LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Home・Akciju saraksts・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Slēgts

SektorsVeselības aprūpe

14.83 -0.87

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.6

Max

15.05

Galvenie mērījumi
By Trading Economics
Ienākumi	227M
Pārdošana	139M
P/E Sektora vidējais	5.725 108.767
Peļņas marža	163.843
Darbinieki	1,780
EBITDA	1.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+45.02% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.7B
Iepriekšējā atvēršanas cena	15.7
Iepriekšējā slēgšanas cena	14.83

Ziņu noskaņojums

By Acuity

50%

161 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

14.24 / 14.78 Atbalsts un pretestība

Hutchison China MediTech Ltd ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. febr. 23:07 UTC

Peļņas

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 23:01 UTC

Peļņas

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:59 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026. g. 24. febr. 22:42 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026. g. 24. febr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026. g. 24. febr. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026. g. 24. febr. 23:36 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026. g. 24. febr. 23:30 UTC

Tirgus saruna

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. febr. 23:16 UTC

Peļņas

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026. g. 24. febr. 23:13 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026. g. 24. febr. 23:12 UTC

Peļņas

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026. g. 24. febr. 23:08 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026. g. 24. febr. 23:07 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026. g. 24. febr. 22:52 UTC

Peļņas

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 22:46 UTC

Peļņas

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:31 UTC

Iegādes, apvienošanās, pārņemšana

Warner Receives New Bid From Paramount -- 3rd Update

2026. g. 24. febr. 22:29 UTC

Peļņas

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026. g. 24. febr. 22:28 UTC

Peļņas

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026. g. 24. febr. 22:25 UTC

Peļņas

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026. g. 24. febr. 22:24 UTC

Peļņas

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026. g. 24. febr. 22:23 UTC

Peļņas

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths Interim Dividend 45 Australian Cents/Share

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026. g. 24. febr. 22:21 UTC

Peļņas

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Salīdzinājums

Cenas izmaiņa

Hutchison China MediTech Ltd ADR Prognoze

Cenas mērķis

By TipRanks

45.02% augšup

Prognoze 12 mēnešiem

Vidējais 22 USD 45.02%

Augstākais 22 USD

Zemākais 22 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Hutchison China MediTech Ltd ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Hutchison China MediTech Ltd ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

14.24 / 14.78Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Noskaņojums

By Acuity

161 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.